Member Info for dk18670

Stephen Koo, Chairman of UniVision, has today purchased 500,000 ordinary shares of HKD0.0625 each in the Company ("Ordinary Shares") at a price of 0.45 pence per Ordinary Share (the "Share Purchase").

Stephen Koo, Chairman of UniVision, purchased 500,000 ordinary shares of HKD0.0625 each in the Company ("Ordinary Shares") on 03 April 2012 at a price of 0.52 pence per Ordinary Share (the "Share Purchase"). Following the Share Purchase, Mr Koo now has a total beneficial interest in 276,453,700 Ordinary Shares in the Company.

Stephen Koo, Chairman of UniVision, has today purchased 1,250,000 ordinary shares of HKD0.0625 each in the Company ("Ordinary Shares") at an average price of 0.585 pence per Ordinary Share.

Stephen Koo, Chairman of UniVision, has today purchased the 100,000 ordinary shares of HKD0.0625 each in the Company ("Ordinary Shares") bought by UniVision on 24 February 2012 at a price of 0.6 pence per Ordinary Share (the "Share Purchase"). These shares were originally purchased in the market by UniVision with the intention of being transferred into treasury by the Company, for redistribution to employees of UniVision as a bonus at some time in the future. The Directors are of the view that the costs of setting up and administering the treasury facility outweigh the benefits at the current time. It remains the intention of the Company to incentivise its employees through the redistribution of repurchased shares as a bonus however the Directors are currently exploring the most effective method of distributing shares to employees.

UniVision, the AIM listed Hong Kong based designer and installer of digital surveillance and integrated security systems, announces that on 08 February 2012, Stephen Koo, Chairman of UniVision, purchased 2 million shares in the Company at an average price of 0.45 pence per share. Following this share purchase, Mr Koo now has a total beneficial interest in 274,103,700 ordinary shares in the Company.

Result of Annual General Meeting UniVision, the Hong Kong based designer and installer of digital surveillance and integrated security systems, announces that at the Group's annual general meeting, held on 29 October 2011 at 8/F Lever Tech Centre, 69-71 King Yip Street, Kwun Tong, Kowloon, Hong Kong, all resolutions were duly passed. Amongst the resolutions passed was the resolution to approve the repurchase of UniVision's ordinary shares in the market by the Company. The Board now has the authority, at its discretion, to buy back over the next 15 months or until the Company's next AGM, whichever occurs sooner, ordinary shares of HK$0.0625 each in UniVision.

On 20 April 2011, the board of Eatonfield announced that the Group had sufficient working capital funding through to early May 2011. This was on the basis that (i) Eatonfield continued to defer payment of amounts due to certain of its senior lenders and trade creditors; (ii) exchange of contracts for the previously notified sale of the Welsh sites was imminent; and (iii) following exchange, the Group would have access to the new £0.25 million RBS working capital facility. Exchange of contracts for the sale of the Welsh sites has not as yet taken place. The board remains of the view that discussions prior to exchange are now in the final stages. The terms of the proposed transaction are also as previously described in the Group's 11 April 2011 announcement. The board also confirms that, as at the date of this announcement, the new RBS facility remains available to the Group pending exchange. In light of the above matters, Eatonfield continues to defer payment of amounts due to certain of its senior lenders and trade creditors. On the basis that the relevant lenders and trade creditors do not demand payment in the short-term and that Eatonfield continues to receive their support, the board now expects that the Group's existing financial resources will provide it with sufficient working capital funding until mid to late May 2011. The board confirms that all of the Group's existing bank facilities remain available at the date of this announcement. The Group's program of presentations to potential equity investors is also ongoing as at the date of this announcement and a further update will be provided in due course.

On 1 February 2011, the board of Eatonfield announced that the Group had sufficient working capital funding through to late February 2011. The board can confirm that terms have been agreed for a short-term loan to be made available to the Group, to be secured on a previously unencumbered property. Eatonfield also continues to defer payment of amounts due to certain of its senior lenders and trade creditors. On the basis that the relevant lenders and trade creditors do not demand payment in the short-term and that Eatonfield continues to receive their support, the board now expects that the Group's existing financial resources will provide it with sufficient working capital funding until mid March 2011. The board believes that the previously notified negotiations for the sale of the Group's Welsh land portfolio and agreement of related follow-on housebuilding contracts are nearer to being finalised, with the consent of the Group's lenders to these arrangements being the main condition outstanding to be satisfied prior to completion. Following conclusion of these negotiations, the board repeats its intention to seek agreement to similar arrangements for the Group's Corus and Birkwood sites as well as pursue plans to raise further equity. The board also confirms that all of the Group's existing bank facilities remain available at the date of this announcement.

Hard-pressed vascular disease and cancer specialist Ark Therapeutics (AKT) is selling most of its loss-making woundcare business for up to £2.7 million. The fully-listed company, which is no longer seeking partners for its Cerepro brain tumour treatment after approval delays, is to receive £765,000 cash for the woundcare activities from Crawford Healthcare and another £1.93 million if and when certain revenue and other milestones are met. Though Ark did receive expressions of interest from several parties the woundcare business remains loss making and achieved sales of approximately £2.2 million last year. By selling the operation it reduces headcount by 16 people and extends the cash runway for the group. Chief executive Martyn Williams told Growth Company Investor 'we are pleased with the value achieved for the sale and look forward to the future with confidence'. The move follows a fundamental strategic review of Ark's operations carried out last autumn by chief executive Martyn Williams and colleagues in the light of Cerepro setbacks, reduced interim losses of £10 million and abortive bid talks with a potential suitor. The company, which changed brokers in December with the appointment of Matrix Corporate Capital, is now focusing on its EG013 treatment for foetal growth restriction, 'early-stage' projects and manufacturing for other companies at its specialist facility in Finland. Ark, which had £14.1 million in the bank last June, reported 'very promising results' before Christmas from EG013 research programmes. However investors, who have seen the shares collapse from more than 150p in 2007 to 4.5p now, valuing the company at £9.4 million remain wary. At current levels we rate Ark as a speculative buy.

Working capital funding update On 20 December 2010, the board of Eatonfield announced that the Group had sufficient working capital funding through to late January 2011. Eatonfield continues to defer payment of amounts due to certain of its senior lenders and trade creditors to a later date. On the basis that the relevant lenders and trade creditors do not demand payment in the short-term and that Eatonfield continues to receive their support, the board now expects that the Group's existing financial resources will provide it with sufficient working capital funding until late February 2011. The board believes that the previously notified negotiations for the sale of the Group's Welsh land portfolio and agreement of related follow-on housebuilding contracts, both of which remain subject to the consent of the Group's lenders, are now approaching the final stages. Following conclusion of these negotiations, the board then intends to seek agreement to similar arrangements for the Group's Corus and Birkwood sites as well as pursue plans to raise further equity. The board also confirms that all of the Group's existing bank facilities remain available at the date of this announcement.

Disposal of the brands and certain assets of the travel division The Board of Western & Oriental, the luxury and specialist travel group, announces that, having consulted with a number of its major shareholders, it has accepted, subject to contract and conditional on shareholder approval, an offer for the brands and certain assets of the Travel Division of the Company ("the Travel Business") by Furze International Limited (the "Proposed Transaction"). Background to the Transaction During the strategic review commenced in 2010 and discussed further over the last two months, a number of options available to the Board have been reviewed and investigated. The Board concluded that of the available options, a sale of the Travel Business would be an appropriate course of action for the Group. The Board also concluded that the sale of the Travel Business would enable the Company to increase its focus and apply its resources to the development of its profitable Events Division. The Board of the Company has, further to the announcement made on 26 January 2011 entered into extensive discussions with two interested parties. Only one of those parties, Furze International Limited ("the Purchaser"), which is owned by the Kumar Family Trust of which Raj Kumar, a Director of the Company, is a beneficiary, has confirmed its offer on terms acceptable to the Board. Summary terms of the offer The terms of the offer made by the Purchaser are: 1. Cash consideration of £1m. The consideration will be effected by the deemed repayment of the £800,000 loan, which Mr Kumar has provided to the Company, as announced on 21 December 2010, and the balance of £200,000 to be paid in cash on completion of the Proposed Transaction which is envisaged to take place as soon as the requisite shareholder approval is obtained. If the Proposed Transaction does not gain sufficient shareholder support the Company will need to repay the £800,000 loan in cash or convert it into shares or a combination of the two; 2. The Purchaser will acquire all the brands and certain assets of the Travel Business, specifically the forward order book as at 31 January 2011 and net customer monies relating to those forward orders stands at £3,845,000 ; 3. The Purchaser will take over the lease of all properties operated by the Travel Business as well as the remaining 4 years of the existing lease of the Group's head office, Welby House in Victoria. Whilst the Company intends to continue to sub-lease part of Welby House for its Events and corporate operations, it is anticipated that the transfer of the remaining lease obligations of Welby House and the other properties will result in a saving of approximately £300,000 per annum for the next four years, when the last of the existing leases expire. 4. All employees, including Kerry Golds who is a Director of the Company, connect

Environmental Consultants White Young Green (WYG) has bought privately owned transport specialists Savell bird and Axon (SBA) in an £18 million deal. SBA provides transport advice to the property industry throughout the UK and is recognised as a leader in their field. It has offices in London, Manchester and Cardiff. Its clients include many of the UKs leading property solutions to transport problems. The transport company, formed in 1994 by Andrew Savell, David bird and Michael Axon has over 70 staff and an annual turnover of approximately £8m. Lawrie Haynes, Chief Executive said: High level transportation consultancy has been identified as strategically important for the future development of the WYG Group and I am delighted that Savell bird and Axon has joined the business. SBA brings with it a market leading pedigree of expertise with an excellent reputation and strong client base. The SBA team will significantly strengthen our own growing profile as well as being a good strategic fit into our multi-discipline business.

Directorate changes and Update on Strategy Board Changes Further to the announcement on 18 January 2011, Western & Oriental plc, the luxury and specialist travel group, announces that at a Board meeting held on 25 January 2011, Pavlos Savvides was appointed Chairman of the Company with immediate effect. The Company also announces that Jeremy Goldberg has resigned as a Director of the Company with effect from 25 January 2011. The Board are in the process of considering the appointment of additional Non-Executive Directors and will look to complete this process by end February 2011. Strategy Update - Sale of tour operating business The Board, further to the announcement on 1 December 2010, also wishes to inform the market of its intentions regarding the strategy of the Company going forward. As part of the strategic review initiated by the previous Board, a number of parties have expressed interest to acquire the tour operating business of the Company and as a result five offers for the business have been received. Having evaluated these offers the board has concluded that it will proceed with two of the parties, being those who had made the highest offers and having minimal conditions, subject to a substantial deposit being received by 31 January 2011 and subject to completion of the sale by 28 February 2011. The transaction will result in the Company disposing of the brands and assets relating to the tour operating business, including forward bookings and customer monies relating to those bookings. To ensure that the Company is able to proceed with an appropriate sale of the business during this period Raj Kumar, a Director of the Company, has agreed to extend his shareholder loan until 28 February 2011. Completion of any transaction that would involve the sale of the tour operating business will be subject to shareholder approval which will be sought at a General Meeting. Further details will be announced in due course.

Eatonfield Group plc ("Eatonfield" or "the Group") Notice of Annual General Meeting Notice of the Annual General Meeting ("AGM") of Eatonfield to be held at 11.00 a.m. on 31 December 2010 at the Company's registered office has been sent to shareholders together with a form of proxy. The Notice of AGM can be viewed on the Company's website www.eatonfield.co.uk. As previously notified, the Group remains in discussions with its banks and continues to progress a range of strategic options, including the disposal of certain of its land assets as well as plans to raise further equity. The directors intend to finalise the Annual Report and Accounts for the year ended 30 June 2010 once these matters have been concluded. The Annual Report and Accounts will then be signed off and sent to shareholders.

UniVision, the AIM listed Hong Kong based designer and installer of digital surveillance and integrated security systems, today provides an update on the litigation proceedings with Mr June Kam Ming Ip ("Mr Ip"), a former director and legal representative of Leader Smart Engineering (Shanghai) Limited ("Leader Smart Shanghai"), the Group's wholly owned subsidiary in the People's Republic of China ("PRC"). This is further to the announcement released by the Group on 16 July 2010, the update on the litigation provided by the Group at the time of its full year results announced on 9 September 2010 and the further update provided on 12 October 2010. Leader Smart Shanghai have applied for and successfully obtained all of Leader Smart Shanghai's chops*, business licences and the legal representative's chop back from Mr Ip through the local authorities in Shanghai. As a result the legal representative of Leader Smart Shanghai has now been changed with immediate effect from Mr Ip to Stephen Koo, Chairman of UniVision. The only documents waiting to be returned to the Group in respect of the litigation proceedings are the accounting records of Leader Smart Shanghai. UniVision's legal attorney has issued a final notice to Mr Ip and the former finance manager of Leader Smart for the surrender of these accounting records to the Group. The due date for return of the accounting records has expired and as a result the Company has commenced legal action. The Group will be announcing its interim results for the six months to 30 September 2010 by 31 December 2010. UniVision will not however be in a position to re-consolidate the accounts of Leader Smart Shanghai into the Group's interim results. This is as a result of the accounting records for Leader Smart Shanghai having not been returned to the Group at this stage. The Board are confident of being in a position to be able to re-consolidate Leader Smart Shanghai's accounts into the Group's annual accounts for the 12 months ended 31 March 2011. The Group will provide a further update on the litigation with Leader Smart Shanghai at the appropriate time.

Holidaybreak, the UK-based firm that sells Eurocamp and Keycamp holidays – and owns the Superbreak, djoser, PGL Travel, weekendjeweg, and EXPLORE! travel brands – has confirmed that they have paid £30.9 million for a 50% hold in Meininger, the German travel firm. The company says that they will merge the German business with their PGL Travel subsidiary, which will help them expand their education travel division. Shares in the company jumped 11p to 218p. Martin Davies, the chief executive of Holidaybreak and the former head of PGL Travel, said that education will be part of the company’s strategy to take core skills to new European markets. This takeover will provide them with earnings revenues by branching the business into areas where they have knowledge and expertise, he continued, enhancing earnings from the very first day. Davies also said that the tailored accommodation business model for PGL Travel is well suited for Meininger, which is popular among teachers searching for appropriate student lodging at European cities. The first thing the group will do is expand tours in key cities like Milan, Amsterdam, Paris and Berlin. This move comes as Holidaybreak announces full-year results for the year ending September 30. Profits soared from £2.6 million to £20.2 million, while pretax profits rose from £5.2 million to £26 million. These healthy figures are a result of growing demand for educational tours. Chairman John Coleman says that the group has performed well against the difficult economic environment. Visibility is still high for their education businesses, despite the outlook for next year expected to be challenging, he added.

On 29 October 2010, the board of Eatonfield announced that the Group had sufficient working capital funding through to mid November 2010. Eatonfield has since agreed with one of its banks that the Group can retain the surplus cash flows generated on a recently concluded housebuilding contract and apply these to fund working capital. The Group has also obtained the agreement of certain of its creditors to defer payment of outstanding invoices to a later date. On this basis, the board now expects that Eatonfield's existing financial resources will provide it with sufficient working capital funding until mid December 2010. As previously notified, certain of the Group's banking facilities fell due for renewal on 30 September 2010. Whilst the Group has not received formal notice of extension of such facilities, the board remains in constructive discussions with the relevant lenders and all of the Group's existing banking facilities remain available at the date of this announcement and the board continues to make progress with a range of strategic options, including the disposal of certain of its land assets, which, if successful, would reduce the Group's net debt, as well as a plan to raise further equity.

Circadian Technologies announced that it amicably settled the previously announced arbitration proceedings instituted against Lymphatix Ltd, a 100 per cent owned subsidiary of Ark Therapeutics Group plc relating to Ark’s product Trinam. Under the settlement, both parties have agreed to terminate the arbitration process and to bear their own costs incurred to date. Under the settlement, Circadian, through its 100 per cent owned subsidiary Vegenics Limited, will now receive an increased annual licence payment and royalties on any commercialisation income generated from Trinam. In return, Vegenics has granted Lymphatix an exclusive worldwide licence under its VEGF-D patent portfolio for VEGF-D gene therapy products including Trinam. Trinam is a potential agent for inhibiting stenosis of venous access grafts in renal dialysis patients. Ark has announced that as part of its ongoing strategy it will be seeking partners to fund ongoing clinical development of this molecule. Trinam is a novel product consisting of a local delivery device and VEGF-D gene, being developed to prevent the blocking of blood vessels that frequently occurs after vascular surgery. The initial target market is haemodialysis graft access surgery, a procedure in which patients whose kidneys have failed have a plastic tube grafted between blood vessels generally in their forearm so that their blood can be regularly filtered using a dialysis machine. Trinam has completed a phase IIa trial and recently started patient enrolment within a large phase IIb, randomised, controlled study which expects to recruit up to 50 patients. Circadian is a biologics drug developer focusing on cancer therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF) C and D.

Ark Therapeutics Group plc Interim Management Statement 11 November 2010 - Ark Therapeutics Group plc ('Ark' or the 'Company') today publishes its interim management statement for the period from 1 July 2010 to date. Highlights · Major business restructuring and strategic repositioning announced 9 September · Interest in Ark's novel Neuropilin-1 programme from a number of pharma companies confirmed; discussions ongoing · Late-stage discussions continue for sale of Woundcare business, completion anticipated early 2011 · Significant interest in Ark's manufacturing capabilities, detailed discussions with a number of parties have commenced · Cost reduction initiatives implemented; cash expected to last into 2013

Estate plan is refused amid pricing row A bid to build a 21-home estate in Rhayader has been refused, after a row over affordable housing and recreation facilities. Developers Eatonfield Homes applied for permission to build the estate in 2008, and members of Powys County Council’s planning committee resolved in September of that year to delegate approval to the then head of regeneration and environment, subject to the provision of seven affordable housing units. Committee members heard at a meeting on Tuesday that no such undertaking had been given. “The applicant has stated that the affordable housing provision would make the development unviable, having regard to the land owners’ aspirations on land value,” said case officer Gwilym Davies in a report to members. “A robust viability statement has not been submitted in support of the application to justify fewer than seven affordable housing units, neither has any information been submitted to justify less than this number on the basis of affordable housing need in the area. “It is also considered that, given that the applicant is yet to purchase that land, the land value should reflect the required affordable housing provision.” In addition, he said the developer had been asked to contribute to off-site outdoor play facilities, as construction of the proposed estate would lead to a shortfall in provision. “To date, no off-site contribution figure has been agreed,” he reported. “The applicant has noted that off-site play facilities were not included in the original committee report and in light of the affordable housing contribution feels aggrieved that a contribution is being sought.” Planning committee members voted to refuse planning permission.